| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cyclopamine is a natural steroidal alkaloid derived from the corn lily, Veratrum californicum, which specifically disrupts the Hh signaling pathway. Cyclopamine — Cyclopamine is a natural steroidal alkaloid Hedgehog pathway antagonist derived from the corn lily Veratrum californicum. It is formally a small-molecule phytochemical / steroidal alkaloid and experimental Smoothened inhibitor. Cyclopamine is best treated as a preclinical tool compound and pharmacologic scaffold rather than a clinically deployed anticancer drug, because systemic translation is constrained by poor solubility, acid instability, limited pharmacokinetics, and developmental toxicity risk. Primary mechanisms (ranked):
Bioavailability / PK relevance: Cyclopamine has poor aqueous solubility, acid-sensitive conversion to less active products under gastric-like conditions, and suboptimal systemic pharmacokinetics. These constraints explain why clinically used Hedgehog inhibitors are synthetic SMO inhibitors or derivatives rather than cyclopamine itself. In-vitro vs systemic exposure relevance: Many in-vitro studies use micromolar cyclopamine concentrations, often exceeding what is realistically attractive for systemic exposure with the parent compound. Interpretation should therefore distinguish pathway-probe activity from clinically achievable drug exposure. The compound is concentration-driven, not field-based or device-based. Clinical evidence status: Preclinical tool compound. Cyclopamine has strong mechanistic and animal-model evidence for Hedgehog pathway inhibition, but it is not an approved anticancer drug and has not become a standard clinical intervention. Clinical translation of this mechanism is represented by approved SMO inhibitors such as vismodegib, sonidegib, and glasdegib, not by cyclopamine itself. Cyclopamine cancer mechanism table
P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: |
| Type: |
| Oxygen consumption rate (OCR) is a measure of the rate at which cells consume oxygen, and it has been found to be altered in cancer cells. Cancer cells often exhibit increased glycolysis, a process in which glucose is converted into energy without the use of oxygen, even in the presence of oxygen. This is known as the Warburg effect. Cancer cells often exhibit increased glycolysis, which leads to a decrease in OCR. -When mitochondrial function is impaired (resulting in lower OCR), cells may compensate by upregulating glycolysis to meet their energy needs (known as the Pasteur effect). -Instruments such as the Seahorse Analyzer allow simultaneous measurement of OCR (reflecting mitochondrial respiration) and Extracellular Acidification Rate (ECAR, which is commonly used as a proxy for glycolysis). This dual measurement helps researchers understand how shifts in one pathway correlate with compensatory changes in the other. |
| 6249- | Cyc, | Cyclopamine tartrate, an inhibitor of Hedgehog signaling, strongly interferes with mitochondrial function and suppresses aerobic respiration in lung cancer cells |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | NSCLC, | H1299 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:66 Target#:846 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid